Entospletinib monotherapy in patients with relapsed or refractory chronic lymphocytic leukemia previously treated with B-cell receptor inhibitors: results of a phase 2 study

Farrukh T. Awan, Michael J. Thirman, Dipti Patel-Donnelly, Sarit Assouline, Arati V. Rao, Wei Ye, Brian Hill, Jeff P. Sharman

Research output: Contribution to journalArticle

2 Scopus citations


Entospletinib (GS-9973), an oral, selective inhibitor of spleen tyrosine kinase (SYK), was evaluated as monotherapy in this multicenter, phase 2 study (NCT01799889) of 49 patients with relapsed or refractory chronic lymphocytic leukemia (CLL), including those with Richter’s transformation (RT), who had received prior therapy with a B-cell receptor (BCR) inhibitor. Patients were treated with entospletinib 400 mg BID as the starting dose. Sixteen patients achieved partial response and 21 had stable disease. The overall response rate was 32.7% (95% confidence interval [CI]: 21.7–45.3%). The median progression-free survival (PFS) was 5.6 (95% CI: 3.7–8.3) months. Twenty-one (of 43) patients (48.8%) experienced nodal response. Adverse events (AEs) occurred in all patients; most commonly fatigue, diarrhea, and anemia. Entospletinib monotherapy has clinical activity for patients with CLL and RT who have relapsed following therapy with BCR inhibitors.

Original languageEnglish (US)
Pages (from-to)1972-1977
Number of pages6
JournalLeukemia and Lymphoma
Issue number8
StatePublished - Jul 3 2019
Externally publishedYes



  • B-cell receptor inhibitors
  • Richter’s transformation
  • SYK

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this